Septerna Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jeff Finer
Chief executive officer
US$4.7m
Total compensation
| CEO salary percentage | 11.66% |
| CEO tenure | 4yrs |
| CEO ownership | 1.9% |
| Management average tenure | 3.1yrs |
| Board average tenure | 2.9yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$88m |
| Mar 31 2025 | n/a | n/a | -US$79m |
| Dec 31 2024 | US$5m | US$550k | -US$72m |
| Sep 30 2024 | n/a | n/a | -US$20m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$4m |
| Dec 31 2023 | US$2m | US$501k | US$567k |
Compensation vs Market: Jeff's total compensation ($USD4.72M) is above average for companies of similar size in the US market ($USD3.47M).
Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.
CEO
Jeff Finer (58 yo)
Dr. Jeffrey T. Finer, also known as Jeff, M.D. & Ph D., serves as Consultant of Kainomyx, Inc. He is Co-Founder & Director of Septerna, Inc. and serves as its Chief Executive Officer from September 2022 an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 4yrs | US$4.72m | 1.85% $ 17.0m | |
| President & COO | 3.4yrs | US$1.62m | 0.39% $ 3.6m | |
| Chief Medical Officer | 1.2yrs | US$2.12m | no data | |
| Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | no data | no data | no data | |
| Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | no data | no data | no data | |
| Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | no data | no data | no data | |
| Chief Financial Officer | less than a year | no data | 0.090% $ 824.0k | |
| Vice President of Technology | no data | no data | no data | |
| Senior Director of Corporate Development & Portfolio Strategy | 2.8yrs | no data | no data | |
| Chief People Officer | 2.8yrs | US$771.85k | 0% $ 0 | |
| Senior Vice President of Drug Discovery | 4.1yrs | US$646.74k | 0.21% $ 1.9m | |
| Senior Vice President of Biological Sciences | 4.3yrs | US$578.53k | 0.29% $ 2.6m |
Experienced Management: SEPN's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 4yrs | US$4.72m | 1.85% $ 17.0m | |
| Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | 2.9yrs | no data | no data | |
| Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | 2.9yrs | no data | no data | |
| Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | 2.9yrs | no data | no data | |
| Independent Director | 1.8yrs | US$278.91k | 0% $ 0 | |
| Chairman of the Board | 5.9yrs | US$129.32k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$181.90k | 0% $ 0 | |
| Director | 2.9yrs | US$123.31k | 0.26% $ 2.4m | |
| Member of Cross-Functional Scientific & Drug Discovery Advisory Board | 2.9yrs | no data | no data | |
| Independent Director | 4yrs | US$125.62k | 0% $ 0 | |
| Member of Cross-Functional Scientific & Drug Discovery Advisory Board | 2.9yrs | no data | no data | |
| Member of Cross-Functional Scientific & Drug Discovery Advisory Board | 2.9yrs | no data | no data |
Experienced Board: SEPN's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 18:42 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Septerna, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Eric Joseph | J.P. Morgan |